#1
#1 out of 2
politics15h ago
White House digs in on ‘most-favored nation’ drug pricing despite Congress’ cool reception
- White House intensifies pressure on lawmakers to codify MFN drug pricing amid limited congressional receptivity.
- Administration aims to lower U.S. medicine costs by tying prices to those paid by peer countries.
- Republicans on Capitol Hill have characterized the MFN pricing effort as government overreach.
- Two Trump administration officials briefed the discussions on MFN pricing and health policy.
- The White House is pursuing MFN pricing as part of broader health-care reform pressure strategy.
- Experts warn MFN pricing could face a cool reception from Congress.
- The report frames MFN talks within the broader debate over pharmaceutical pricing policy.
- The story appears as an exclusive STAT+ piece, indicating subscriber-only context.
- The MFN approach targets drug pricing reforms that could affect patients directly.
- The White House keeps pressing forward despite limited legislative momentum.
Vote 0
